Cancer Biomarkers - Volume 20, issue 2

Authors: Zhao, Xue | Sun, Zhigui | Li, Hui | Jiang, Feng | Zhou, Jing | Zhang, Linghua

Article Type: Research Article

Abstract: Thyroid carcinoma is one of the most frequent malignant tumors of the endocrine system, which accounts for nearly 1% population in newly diagnosed carcinoma worldwide and the incidence has an increasing tendency in recent years. To explore whether miR-135a-5p could affect the proliferation, invasion and migration of thyroid carcinoma cells by targeting VCAN . The expression levels of miR-135a-5p and VCAN were detected in human thyroid carcinoma tissues and cells, para-carcinoma tissues, as well as human normal thyroid cells using RT-qPCR and Western blot. In addition, dual-luciferase reporter gene assay, MTT assay, colony formation assay, wound healing assay, Transwell …assay, flow cytometry analysis and in vivo tumorigenesis assay were also conducted. The results demonstrated that miR-135a-5p was down-regulated while VCAN was up-regulated both in thyroid carcinoma tissues and cells. Furthermore, the up-regulation of miR-135a-5p inhibited cell proliferation, invasion and migration of thyroid carcinoma. Dual-luciferase reporter gene assay provided evidence indicating that miR-135a-5p targeted VCAN in thyroid carcinoma. MiR-135a-5p could inhibit cell proliferation, invasion and migration of thyroid carcinoma by targeting VCAN . MiR-135a-5p and VCAN might emerge as a target for the treatment of thyroid carcinoma. Show more

Keywords: Thyroid carcinoma, miR-135a-5p, VCAN

DOI: 10.3233/CBM-170566

Citation: Cancer Biomarkers, vol. 20, no. 2, pp. 207-216, 2017

Authors: Lin, Li | Chen, Dong | Xiang, Zhen-Fei | Pei, Ren-Zhi | Zhang, Pi-Sheng | Liu, Xu-Hui | Du, Xiao-Hong | Lu, Ying

Article Type: Research Article

Abstract: OBJECTIVE: In spite of bortezomib being developed and demonstrated as a safe drug therapy for multiple myeloma (MM), the role of bortezomib-induced receptor activator of nuclear factor (NF)-κ B ligand (RANKL) in the MM cell lines remains to be understood. Thus the present study aims to explore the impact of bortezomib on RANKL expression, cell growth and apoptosis in human myeloma cell line RPMI 8226. METHODS: Four experiment groups were set according to different concentrations of bortezomib, namely blank group (treated with DMEM solution free of other drugs), low-dose group (treated with 10 nmol/L …bortezomib), middle-dose group (treated with 20 nmol/L bortezomib) and high-dose group (treated with 40 nmol/L bortezomib). Western blotting was adopted to detect RANKL protein expression. MTT assay was performed to detect cell proliferation. Flow cytometry was used to analyze cell cycle and apoptosis. Spectrophotometry was applied to determine caspases-3 activity. RESULTS: Compared with the blank group, the RANKL protein expression, cell number at the S stage was reduced while cell inhibition rate, cell apoptosis rate and caspase-3 activity enhanced remarkably in the low-dose, middle-dose and high-dose groups with dose-dependent manner. Compared with those treated with bortezomib (20 nmol/L and 40 nmol/L) for 6 h, the RANKL expression was down-regulated, cell inhibition rate was increased, cells at the S stage were reduced, cell apoptosis rate was enhanced, and caspase-3 activity elevated in the RPMI 8226 cells as treated with bortezomib for 24 h, with a dose- and time-dependent manner. CONCLUSIONS: Bortezomib could reduce the RANKL expression, inhibit cell proliferation and activate caspase-3 activity to induce cell apoptosis in RPMI 8266 cells. Show more

Keywords: Proteasome inhibitor, bortezomib, receptor activator of NF-κB ligand, multiple myeloma, RPMI 8226, cell proliferation, cell apoptosis

DOI: 10.3233/CBM-170584

Citation: Cancer Biomarkers, vol. 20, no. 2, pp. 217-224, 2017

Authors: Zhou, Meng | Jin, Mei | Wang, Lin | Pan, Ling-Juan

Article Type: Research Article

Abstract: It has been reported that majority of cases of gigantomastia, also known as breast hypertrophy and macromastia, occur during either pregnancy or puberty. Gigantomastia is a rare disorder that does not have a clear etiology or well-established risk factors. We present a 26-year-old female patient who appeared to have pregnancy-associated gigantomastia recurrence, large accessory breast and, ectopic breast tissue at external genital three years after bilateral breast reduction surgery. The patient successively underwent bilateral mastectomy and vulvar tumor resection. Breast hypertrophy and progenital ectopic breast were pathologically confirmed. This the first case of gigantomastia reported worldwide.

Keywords: Breast hypertrophy and macromastia, progenital ectopic breast, vulvar tumor resection, gigantomastia recurrence

DOI: 10.3233/CBM-160450

Citation: Cancer Biomarkers, vol. 20, no. 2, pp. 225-229, 2017